Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT
- PMID: 11493441
- DOI: 10.1182/blood.v98.4.972
Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT
Abstract
Reactivation of the Epstein-Barr virus (EBV) after allogeneic stem cell transplantation (allo-SCT) may evoke a protective cellular immune response or may be complicated by the development of EBV-lymphoproliferative disease (EBV-LPD). So far, very little is known about the incidence, recurrence, and sequelae of EBV reactivation following allo-SCT. EBV reactivation was retrospectively monitored in 85 EBV-seropositive recipients of a T-cell--depleted (TCD) allo-SCT and 65 EBV-seropositive recipients of an unmanipulated allo-SCT. Viral reactivation (more than 50 EBV genome equivalents [gEq]/mL) was monitored frequently by quantitative real-time plasma polymerase chain reaction until day 180 after SCT. Probabilities of developing viral reactivation were high after both unmanipulated and TCD-allogeneic SCT (31% +/- 6% versus 65% +/- 7%, respectively). A high CD34(+) cell number of the graft appeared as a novel significant predictor (P =.001) for EBV reactivation. Recurrent reactivation was observed more frequently in recipients of a TCD graft, and EBV-LPD occurred only after TCD-SCT. High-risk status, TCD, and use of antithymocyte globulin were predictive for developing EBV-LPD. Plasma EBV DNA quantitatively predicted EBV-LPD. The positive and negative predictive values of a viral load of 1000 gEq/mL were, respectively, 39% and 100% after TCD. Treatment-related mortality did not differ significantly between TCD and non-TCD transplants, but the incidence of chronic graft-versus-host disease was significantly less in TCD patients. It is concluded that EBV reactivation occurs frequently after TCD and unmanipulated allo-SCT, especially in recipients of grafts with high CD34(+) cell counts. EBV-LPD, however, occurred only after TCD, and EBV load quantitatively predicted EBV-LPD in recipients of a TCD graft. (Blood. 2001;98:972-978)
Similar articles
-
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.Blood. 2002 Jun 15;99(12):4364-9. doi: 10.1182/blood.v99.12.4364. Blood. 2002. PMID: 12036863 Clinical Trial.
-
Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease.Blood. 2003 Jun 1;101(11):4290-7. doi: 10.1182/blood-2002-10-3001. Epub 2003 Feb 6. Blood. 2003. PMID: 12576337
-
Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation.Blood. 1998 May 15;91(10):3654-61. Blood. 1998. PMID: 9573001
-
Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.Biol Blood Marrow Transplant. 2011 May;17(5):591-7. doi: 10.1016/j.bbmt.2010.08.007. Epub 2010 Aug 21. Biol Blood Marrow Transplant. 2011. PMID: 20732435 Free PMC article. Review.
-
Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.Curr Opin Hematol. 2008 Nov;15(6):576-85. doi: 10.1097/MOH.0b013e328311f438. Curr Opin Hematol. 2008. PMID: 18832928 Review.
Cited by
-
Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder.Clin Transplant. 2012 Sep-Oct;26(5):741-7. doi: 10.1111/j.1399-0012.2012.01608.x. Epub 2012 Mar 4. Clin Transplant. 2012. PMID: 22385033 Free PMC article.
-
Colonic EBV-Associated Lymphoproliferative Disorder in a Patient Treated with Rabbit Antithymocyte Globulin for Aplastic Anemia.Case Rep Gastrointest Med. 2012;2012:395801. doi: 10.1155/2012/395801. Epub 2012 Sep 23. Case Rep Gastrointest Med. 2012. PMID: 23050175 Free PMC article.
-
Real-time PCR in clinical microbiology: applications for routine laboratory testing.Clin Microbiol Rev. 2006 Jan;19(1):165-256. doi: 10.1128/CMR.19.1.165-256.2006. Clin Microbiol Rev. 2006. PMID: 16418529 Free PMC article. Review.
-
Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options.Paediatr Drugs. 2005;7(1):55-65. doi: 10.2165/00148581-200507010-00005. Paediatr Drugs. 2005. PMID: 15777111 Review.
-
Viral etiology, clinical and laboratory features of adult hemophagocytic lymphohistiocytosis.J Med Virol. 2016 Mar;88(3):541-9. doi: 10.1002/jmv.24359. Epub 2015 Oct 19. J Med Virol. 2016. PMID: 26287378 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources